Rifaximin in Cirrhosis: Effects on Endotoxin and Haemostatic Indexes
Status:
TERMINATED
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
Rifaximin is an antibiotic that acts locally in the gastrointestinal tract with a broad spectrum of antibacterial activity. The efficacy of rifaximin is well documented in the prevention of acute hepatic encephalopathy. There is no evidence on its benefit to modulate hypercoagulative state in cirrhotic patient.
To assess the effect of a short-term treatment with rifaximin on systemic levels of intestinal endotoxin and on platelet and coagulation markers in patients with decompensated cirrhosis the study has been planned.